Skip to main content
Fig. 6 | Journal of Neuroinflammation

Fig. 6

From: Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer’s disease

Fig. 6

Tyrosine kinase DDR1 inhibition with nilotinib. Treatment of AD patients with nilotinib may induce multiple mechanisms that include activation of genes that control the execution and completion of autophagy, suggesting clearance of intracellular amyloid and tau that would perhaps reduce plaque burden and affect plasma amyloid and tau. Nilotinib treatment led to downregulation of several pro-inflammatory makers along with reduction of collagen, TIMPs and TGFs that maintain blood vessel integrity and prevent vascular fibrosis. Nilotinib treatment leads to reduction of dopamine breakdown probably via altered vesicular transport and reduction of COMT

Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094